RSRathan M. Subramaniam

Rathan M. Subramaniam

*This is an algorithmically generated author record based on publicly available information.

Rathan M. Subramaniam has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Charles Marcus

    Russell H. Morgan Department of Radiology and Radiological Sciences, Baltimore, Maryland

    13 shared publications
  • Sara Sheikhbahaei

    From the *Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, MD; †Boston University School of Medicine, Boston, MA; ‡Department of Oncology, Sidney Kimmel Comprehensive Cancer Centre, §Armstrong Institute for Patient Safety & Quality, Johns Hopkins School of Medicine; and ∥Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

    12 shared publications
  • Mehdi Taghipour

    From the *Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, MD; †Boston University School of Medicine, Boston, MA; ‡Department of Oncology, Sidney Kimmel Comprehensive Cancer Centre, §Armstrong Institute for Patient Safety & Quality, Johns Hopkins School of Medicine; and ∥Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

    11 shared publications
  • Richard L. Wahl

    Russel H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, 601 N Caroline St/JHOC 3235, Baltimore MD 21287

    7 shared publications
  • Abdel K. Tahari

    Russel H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, 601 N Caroline St /JHOC 3235, Baltimore MD 21287

    6 shared publications
  • Esther Mena

    Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA

    6 shared publications

Latest Publications

  • 18F-FDG PET/CT and Melanoma

    by Esther Mena, Mehdi Taghipour, Sara Sheikhbahaei, Sahar Mirpour, Jennifer Xiao, Rathan M. Subramaniam

    Purpose We aimed to evaluate the added value of performing fourth and subsequent follow-up 18F-FDG-PET/CT scans to clinical assessment and impact on the patient’s management in patients with melanoma. Methods This was a retrospective study of 232 biopsy-proven melanoma patients who underwent 18F-FDG-PET/CT scans. Of these, 71 patients had 4 or more follow-up 18F-FDG-PET/CT scans after completion of primary treatment, with a total of 246 fourth or subsequent follow-up PET/CT scans. The added value of each follow-up PET/CT scan to the patient’s clinical assessment and treatment management was established. Kaplan-Meier plots with a Mantel-Cox log-rank test were used to establish the patient’s overall survival. Results Of the 246 fourth and subsequent follow-up PET/CT scans, 61% (150/246) were negative for malignancy, and 39.0% (96/246) were positive for recurrence/metastases. FDG-PET/CT was helpful in identifying malignancy in 6.5% of the scans performed without prior clinical suspicion, which ruled out malignancy in 28.5% of the scans obtained with prior clinical signs suggestive of recurrence or for secondary therapy assessment. The PET/CT scan resulted in change of the patient’s management in approximately 16.7% (41/246) of the scans. Change in management was significantly greater in patients whose scans were done with prior clinical signs suggestive of malignancy, or for therapy assessment than without prior clinical suspicion (29.3% vs 4.1%; P < 0.0001). Statistically significant difference was seen in the overall survival between patients with at least 1 positive and all negative fourth and subsequent follow-up PET/CT scans at patient level (P = 0.001). Conclusions The fourth and subsequent 18F-FDG-PET/CT scans obtained after completion of primary treatment added value to clinical assessment in patients with melanoma. Patients with clinical signs suggestive of recurrence or metastases or being monitored for treatment response are more likely to benefit from the fourth or subsequent FDG PET/CT than those without prior clinical suspicion.


  • The Current and Evolving Role of PET in Personalized Management of Lung Cancer

    by Esther Mena, Anusha Yanamadala, Gang Cheng, Rathan M. Subramaniam


  • The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin’s lymphoma

    by Mehdi Taghipour, Charles Marcus, Shani Jones, Rutuparna Sarangi, Tyler J. Trahan, Rathan M. Subramaniam

    Objective To evaluate the impact of fourth and subsequent follow-up PET/computed tomography (PET/CT) scans in patients with non-Hodgkins lymphoma (NHL). Materials and methods This retrospective study evaluated all biopsy-proven NHL patients who had more than three follow-up scans after completion of primary treatment from 2000 to 2013 at our academic center. Among 586 patients with NHL who had at least one fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT scan at our institution, a total of 77 patients with 208 fourth and subsequent follow-up 18F-FDG PET/CT scans, were included in the study. The impact of these follow-up scans on the clinical assessment and the management of the patients was evaluated. Results Among 208 fourth and subsequent follow-up scans, 33 were performed with a previous clinical suspicion of recurrence and 175 were performed without a previous clinical suspicion of recurrence. Fourth and subsequent follow-up PET/CT results were useful in excluding tumor in 27.3% of scan times when there was a clinical suspicion of recurrence and in identifying recurrence in 5.1% of scan times when there was no previous clinical suspicion of recurrence. Clinicians changed management after 36.4% (12/33) scans that were performed with previous clinical suspicion of recurrence and 9.2% (16/175) scans that were performed without previous clinical suspicion (P=0.001). Conclusion Fourth and subsequent follow-up PET/CT scans affect the treatment and management of patients with NHL and add value to clinical assessment and management, especially in patients with a previous clinical suspicion of recurrence.


  • Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer

    by Mehdi Taghipour, Sara Sheikhbahaei, Tyler J. Trahan, Rathan M. Subramaniam

    Objective To evaluate the accuracy and value of the fourth and subsequent post-therapy follow-up fluorine-18 fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) scans in the clinical assessment of breast cancer patients. Materials and methods Ninety-two female patients, with a total of 426 fourth and subsequent follow-up PET/CT scans, were retrospectively included. Patients were followed for a median of 23.7 months (range, 0.7–124.4) from the fourth follow-up PET/CT. The diagnostic accuracy of PET/CT, its impact on clinical assessment, patients’ management, and survival outcome were established. Result Of the 426 follow-up PET/CT scans, 264 (62%) were interpreted as positive and 162 (38%) were interpreted as negative. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the fourth and subsequent follow-up PET/CT scans were 97.7, 98.1, 98.8, 96.3, and 97.9%, respectively. Fourth and subsequent follow-up PET/CT were useful in excluding a tumor in 13.4% (39/292) of patients with a clinical suspicion of recurrence and identifying suspected recurrence in 10.5% (14/134) of patients without previous clinical suspicion. A change in management was noted in 6.7% (9/134) of scan times when the scans were performed without previous clinical suspicion of recurrence or therapy response and was 27.7% (81/292) when the scans were performed with clinical suspicion. Overall survival differed significantly between patients with all negative follow-up scans (n=23) and those who had at least one positive follow-up scan (n=69) (hazard ratio of 4.65, P<0.001). Conclusion The fourth and subsequent PET/CT scans performed after the completion of primary treatment led to a change in management in 27.7% of patients when the scans were performed with clinical suspicion and only in 6.7% of patients when performed without clinical suspicion or context.


  • FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy

    by Mehdi Taghipour, Sara Sheikhbahaei, Rick Wray, Nishant Agrawal, Jeremy Richmon, Hyunseok Kang, Rathan M. Subramaniam

    OBJECTIVE. The purpose of this study was to assess the value of posttreatment FDG PET/CT in patients with squamous cell carcinoma of the head and neck (HNSCC) treated with primary surgical resection with or without adjuvant concurrent chemoradiotherapy. MATERIALS AND METHODS. A total of 98 HNSCC patients were treated with primary surgical resection and had undergone PET/CT within 6 months of treatment completion. The accuracy of the scans and the added value to clinical assessment and impact on management were established based on the clinical information before and after each scan. Overall survival of patients was estimated with Kaplan-Meier curves. RESULTS. Of the total 98 scans, 25 (25.5%) were interpreted as positive and 73 (74.5%) as negative. The sensitivity of posttreatment PET/CT was 80.0%; specificity, 89.5%; positive predictive value, 66.7%; negative predictive value, 94.4%; and accuracy, 87.5%. These scans were helpful in excluding tumor in 31.8% of patients with clinical suspicion of residual ...


  • FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer

    by Mehdi Taghipour, Rick Wray, Sara Sheikhbahaei, Jean L. Wright, Rathan M. Subramaniam

    OBJECTIVE. The objective of this study was to assess the value of quantitative PET parameters in the prediction of survival for patients with recurrent breast cancer. MATERIALS AND METHODS. We conducted a retrospective study of 78 women who had recurrent breast cancer identified by biopsy or follow-up examinations from 2000 to 2012. The maximum and peak standardized uptake values (SUVmax and SUVpeak, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for each recurrent lesion at primary, nodal, and distant metastatic sites, with the use of the gradient segmentation method. The optimum cutoff point (i.e., the value with the maximum Youden index, defined as sensitivity plus specificity minus 1) was calculated using the ROC curve. The median follow-up duration was 28.5 months (range, 0–94 months). The primary outcome measure was overall survival (OS). Kaplan-Meier survival plots and Cox regression analyses were performed. RESULTS. The mean (± SD) values noted for the...


  • 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma

    by Sara Sheikhbahaei, Rick Wray, Brenda Young, Esther Mena, Mehdi Taghipour, Arman Rahmim, Rathan M. Subramaniam

    Objectives This study aims to evaluate the impact of therapy assessment PET/computed tomography (CT) scan on the management of locally advanced pancreatic adenocarcinoma (LAPC), and the value of qualitative versus quantitative PET/CT interpretation for patient outcome prediction. Materials and methods Forty-two LAPC patients were retrospectively included. PET/CT was performed at a median of 4.6 weeks after completion of chemo±radiotherapy to assess the primary treatment response. PET was interpreted visually using a qualitative five-point scale (Hopkins criteria for therapy assessment). Quantitative PET parameters including maximum and peak standardized uptake value (SUVmax and SUVpeak), total lesion glycolysis, and metabolic tumor volume (MTV) were also measured using the gradient segmentation method. Kaplan–Meier and Cox regression analyses were performed. Results Thirty-five patients were followed up until death. Therapy assessment PET/CT led to a change in the overall management of 22 (52.4%) patients, prompting surgical resection (eight patients), adding radiation therapy (eight patients), or starting palliative chemotherapy (six patients). The median survival in patients with a negative or a positive PET scan, according to the Hopkins criteria, was 14.6 and 8.7 months, respectively (P=0.06). The median quantitative thresholds of SUVpeak 2.64 [hazard ratio (HR)=2.67, P=0.03], total lesion glycolysis 44.0 g (HR=2.64, P=0.005), and MTV 24.7 ml (HR=2.57, P=0.008) were significant predictors of overall survival. Using combined quantitative scoring, patients with high SUVpeak and high MTV (>median cut point) had a 5.45-fold (95% confidence interval: 1.76–16.87) increased risk for death compared with those with both low SUVpeak and MTV (the reference group). Conclusion PET-based volumetric parameters can predict survival outcomes of patients with LAPC. A combined quantitative PET/CT scoring system provides significantly improved prognostication.


  • 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients

    by Sara Sheikhbahaei, Esther Mena, Charles Marcus, Rick Wray, Mehdi Taghipour, Rathan M. Subramaniam

    The purpose of this study was to evaluate the value of a FDG-PET/CT based Hopkins interpretation system to assess the therapy response and survival in lung cancer. Methods: This is an institutional review board approved, retrospective study. A total of 201 patients with biopsy-proven lung cancer, who had a therapy assessment FDG-PET/CT, within 6 months (mean 7.5 weeks) of completion of treatment were included. Patients were primarily treated with surgical resection, chemotherapy, radiation therapy or a combination of these treatmens. PET/CT studies were interpreted by two nuclear medicine physician and discrepancies were resolved by a third reader. The studies were scored using a qualitative 5-point scale for the primary tumor, mediastinum, distant metastatic site, if present, and overall assessment. Scores 1, 2, and 3 were considered negative and scores 4 and 5 were considered positive for residual disease. Patients were followed for a median of 12 months (up to 128 months). Kaplan-Meier plots with a Mantel-Cox log-rank test were performed considering death as the endpoint. Results: Overall, the PET/CT studies were positive in 144 (71.6%) and negative in 57 (28.4%) of patients. There was substantial agreement between two readers (R1, R2) with K= 0.78 (P< 0.001). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the Hopkins scoring system were 89%, 80%, 92.8%, 71.4% and 86.7%, respectively. Overall, PET/CT resulted in starting a new treatment plan in 70.8% of patients with positive residual disease on therapy assessment PET/CT. There was significant difference in OS between patients who were categorized as positive in comparison to those who were categorized as negative (HR= 2.12, 95% confidence interval= 1.44-3.12), which remain significant after adjustment for disease stage, prior clinical suspicion and primary treatment. Subgroup analysis according to the tumor histology showed that positive Hopkins scoring could significantly predict the OS both in small cell lung cancer (HR= 2.88, Logrank P = 0.02) and non-small cell lung cancer (HR= 2.01, Logrank P = 0.001). Similarly, there was a significant difference in OS between patients with positive and negative Hopkins score both in those who had surgical resection as part of the primary treatment (HR= 6.09, Logrank P < 0.001) and those who treated with chemotherapy +/- radiation (HR= 1.60, Logrank PP = 0.02). Conclusion: The 5-point qualitative therapy response interpretation for lung cancer has substantial inter-reader agreement, high accuracy, and could significantly predict survival in lung cancer, irrespective of tumor histology and treatment modality.


  • Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy

    by Rathan M. Subramaniam, Catalina Suarez-Cuervo, Renee F. Wilson, Sharon Turban, Allen Zhang, Cheryl Sherrod, Jonathan Aboagye, John Eng, Michael J. Choi, Susan Hutfless, et al.

    Background: N-acetylcysteine, sodium bicarbonate, statins, and ascorbic acid have been studied for reducing contrast-induced nephropathy (CIN). Purpose: To evaluate the comparative effectiveness of interventions to reduce CIN in adults receiving contrast media. Data Sources: MEDLINE, EMBASE, Cochrane Library, ClinicalTrials.gov, and Scopus databases through June 2015. Risk of bias of studies and overall strength of evidence (SOE) were assessed. Study Selection: Randomized, controlled trials of N-acetylcysteine, sodium bicarbonate, statins, or ascorbic acid that used intravenous (IV) or intra-arterial contrast media and defined CIN with enough data for meta-analysis. Data Extraction: Two reviewers independently extracted data and assessed study quality. Data Synthesis: Low-dose N-acetylcysteine compared with IV saline (risk ratio [RR], 0.75 [95% CI, 0.63 to 0.89]; low SOE), N-acetylcysteine compared with IV saline in patients receiving low-osmolar contrast media (RR, 0.69 [CI, 0.58 to 0.84]; moderate SOE), and statins plus N-acetylcysteine versus N-acetylcysteine (RR, 0.52 [CI, 0.29 to 0.93]; low SOE) had clinically important and statistically significant benefits. The following 3 comparisons suggested a clinically important difference that was not statistically significant: sodium bicarbonate versus IV saline in patients receiving low-osmolar contrast media (RR, 0.65 [CI, 0.33 to 1.25]; low SOE), statins plus IV saline versus IV saline (RR, 0.68 [CI, 0.39 to 1.20]; low SOE), and ascorbic acid versus IV saline (RR, 0.72 [CI, 0.48 to 1.01]; low SOE). Strength of evidence was generally insufficient for comparisons of the need for renal replacement, cardiac events, and mortality. Limitation: Too few studies were done in patients receiving IV contrast media. Conclusion: The greatest reduction in CIN was seen with N-acetylcysteine in patients receiving LOCM and with statins plus N-acetylcysteine. Primary Funding Source: Agency for Healthcare Research and Quality.


  • The Role of Positron Emission Tomography/Computed Tomography in Management and Prediction of Survival in Pancreatic Cancer

    by Pratyusha Nunna, Sara Sheikhbahaei, Sejin Ahn, Brenda Young, Rathan M. Subramaniam

    The role of positron emission tomography (PET) and PET/coirtputed tomogaphy (CT) in the management of pancreatic cancer patients has not been clearly established. Although value of PET/CT in the staging of pancreatic cancer is still being debated, several studies pointed to its superior role in determining therapy response, recurrence detection, and survival prediction in comparison to conventional imaging including contrast -enhanced CT. This article reviews the current literature on usefulness of PET/CT in the management of pancreatic cancer patients.